Showing posts from December, 2007

Impact of Rajendra Pachuri's Nobel Prize on Indian behavior

I have known all along that Al Gore had won the Nobel Peace Prize along with the Inter-governmental Panel on Climate Change, but I didn't know that the IGPCC was being led by an Indian national, Dr. Rajendra Pachuri.  

An immediate impact of this is a greater awareness among the Indians about the perils of global warming. This became clear as I was talking to my dad this morning, who informed me that all over Mumbai people have been asked to turn out their lights for one hour to help against global warming. Thats right, charity does begin at home.
Now if we in the United States can only take this to heart and emulate the Indian grass root efforts by not driving for one day!

Esai buying spree continues

First it was Morphotek, then some drugs from Ligand Pharmaceuticals. Now, Easai has decided to buy MGI pharma, the Bloomington, Minnesotta based maker of Aloxi. With Aloxi, Easai will enter the space of oncology supportive care drugs.

Celgene shares get hammered

This is what happens when a competitor arrives at the door step!
Celgene's shares fell roughly 15 percent to $48.90 on Nasdaq, while Millennium's shares rose nearly 10 percent to $16.53.

Until recently, Millennium's injected drug Velcade has been seen as the underdog to Celgene's more convenient, oral drug Revlimid. But data presented over the weekend at the annual meeting of the American Society of Hematology (ASH) is giving investors greater confidence that Velcade will be able to hold its own.
So, is the Celgene buyout of Pharmion in trouble? Celgene is below the collar lower range of $56.16, and Pharmion shares dropped on the news. As Celgene's stock value falls, the actual value of the Pharmion buyout could suffer, said Banc of America Securities analyst William T. Ho, if the stock price remains below the $56.15 lower boundary of the deal's collar.
Advantage of oral formulation (of Revlemid) can only take one so far.